23 studies found for:
Open Studies | "Nose Neoplasms"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Unknown † |
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
|
||||
| 2 | Recruiting |
Erlotinib Hydrochloride and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
|
||||
| 3 | Recruiting |
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
|
||||
| 4 | Recruiting |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
|
||||
| 5 | Recruiting |
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
|
||||
| 6 | Recruiting |
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
|
||||
| 7 | Recruiting |
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
||||
| 8 | Recruiting |
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
|
||||
| 9 | Recruiting |
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage III-IV Head and Neck Cancer
|
||||
| 10 | Recruiting |
Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)
|
||||
| 11 | Recruiting |
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery
|
||||
| 12 | Recruiting |
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
|
||||
| 13 | Recruiting |
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
|
||||
| 14 | Recruiting |
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
||||
| 15 | Recruiting |
Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses
|
||||
| 16 | Recruiting |
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
|
||||
| 17 | Recruiting |
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
|
||||
| 18 | Not yet recruiting |
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy
|
||||
| 19 | Not yet recruiting |
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
||||
| 20 | Recruiting |
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
|
† Indicates status has not been verified in more than two years
